Silo Pharma, Inc.
SILOHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Silo Pharma, Inc. (SILO) is listed under Biotechnology. The company carries a $2.4M market cap, placing it firmly in the micro-cap category. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases.
Market Cap
$2.4M
Beta
0.91
P/E (TTM)
—
P/E (Fwd)
-1.69
EPS (TTM)
$-4.26
EPS (Fwd)
$-0.70
ROE
-91.2%
ROA
-44.3%
Cash
$5.2M
Total Debt
$0
Free CF
-$1.6M
52W Change
-86.8%
Annual Financials
Cash vs Debt
Where SILO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SILO finished 75.65% below its 150-day moving average ($4.64) and 76.26% below its 200-day moving average ($4.76). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SILO overbought or oversold?
At the October 20, 2026 close, SILO's RSI(14) was 12.7, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Silo Pharma, Inc. reports $5.2M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$1.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -91.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $72K (2022) to $72K (2025).
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Silo Pharma, Inc. and its sector.